Charles River Laboratories’ Post

“By collaborating with Charles River, we are one step closer to beginning clinical trials to ensure our therapeutic for Stargardt’s Disease is safe and efficacious for patients. We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to expanding treatment options for this patient population.” Nina Kotsopoulou, AAVantgarde Bio Taking an avant-garde approach to AAV gene therapy, clinical-stage biotech AAVantgarde Bio is focused on developing AAV platforms to treat inherited retinal diseases. Read the story in full: https://okt.to/DUcPmi #plasmidDNA #AAV #genetherapy #raredisease #stargardtsdisease

“By collaborating with Charles River, we are one step closer to beginning clinical trials to ensure our therapeutic for Stargardt’s Disease is safe and efficacious for patients. We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to expanding treatment options for this patient population.” Nina Kotsopoulou, AAVantgarde Bio Taking an avant-garde approach to AAV gene therapy, clinical-stage biotech AAVantgarde Bio is focused on developing AAV platforms to treat inherited retinal diseases. Read the story in full: https://okt.to/6l1Rnr #plasmidDNA #AAV #genetherapy #raredisease #stargardtsdisease

“By collaborating with Charles River, we are one step closer to beginning clinical trials to ensure our therapeutic for Stargardt’s Disease is safe and efficacious for patients. We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to expanding treatment options for this patient population.” Nina Kotsopoulou, AAVantgarde Bio Taking an avant-garde approach to AAV gene therapy, clinical-stage biotech AAVantgarde Bio is focused on developing AAV platforms to treat inherited retinal diseases. Read the story in full: https://okt.to/Aod3He #plasmidDNA #AAV #genetherapy #raredisease #stargardtsdisease

Taking an avant-garde approach to AAV gene therapy, clinical-stage biotech AAVantgarde Bio is focused on developing AAV platforms to treat inherited retinal diseases. The most prevalent inherited macular dystrophy, representing a high unmet need with no existing therapies available, Stargardt’s disease causes progressive loss of central vision, resulting in significant vision loss. “By collaborating with Charles River, we are one step closer to beginning clinical trials to ensure our therapeutic for Stargardt’s Disease is safe and efficacious for patients. We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to expanding treatment options for this patient population.” Nina Kotsopoulou, AAVantgarde Bio Read the story in full: https://okt.to/x2iSbw #plasmidDNA #AAV #genetherapy #raredisease #stargardtsdisease

Taking an avant-garde approach to AAV gene therapy, clinical-stage biotech AAVantgarde Bio is focused on developing AAV platforms to treat inherited retinal diseases. The most prevalent inherited macular dystrophy, representing a high unmet need with no existing therapies available, Stargardt’s disease causes progressive loss of central vision, resulting in significant vision loss. “By collaborating with Charles River, we are one step closer to beginning clinical trials to ensure our therapeutic for Stargardt’s Disease is safe and efficacious for patients. We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to expanding treatment options for this patient population.” Nina Kotsopoulou, AAVantgarde Bio Read the story in full: https://okt.to/sRjV7Q #plasmidDNA #AAV #genetherapy #raredisease #stargardtsdisease

The most prevalent inherited macular dystrophy, representing a high unmet need with no existing therapies available, Stargardt’s disease causes progressive loss of central vision, resulting in significant vision loss. Taking an avant-garde approach to AAV gene therapy, clinical-stage biotech AAVantgarde Bio is focused on developing AAV platforms to treat inherited retinal diseases. Read the story in full: https://okt.to/br9omI #plasmidDNA #AAV #genetherapy #raredisease #stargardtsdisease

The most prevalent inherited macular dystrophy, representing a high unmet need with no existing therapies available, Stargardt’s disease causes progressive loss of central vision, resulting in significant vision loss. Taking an avant-garde approach to AAV gene therapy, clinical-stage biotech AAVantgarde Bio is focused on developing AAV platforms to treat inherited retinal diseases. Read the story in full: https://okt.to/rBMSGa #plasmidDNA #AAV #genetherapy #raredisease #stargardtsdisease

The most prevalent inherited macular dystrophy, representing a high unmet need with no existing therapies available, Stargardt’s disease causes progressive loss of central vision, resulting in significant vision loss. Taking an avant-garde approach to AAV gene therapy, clinical-stage biotech AAVantgarde Bio is focused on developing AAV platforms to treat inherited retinal diseases. Read the story in full: https://okt.to/TdUyoZ #plasmidDNA #AAV #genetherapy #raredisease #stargardtsdisease

Pursuing a different approach for the treatment of chronic pain associated with rare diseases, Navega Therapeutics will leverage our off-the-shelf plasmid products, custom plasmid capabilities, and GMP-grade AAV production to manufacture its next-gen gene therapy for Phase I clinical trials. With over 17m people in the US alone living with high-impact chronic pain, Navega’s non-opioid gene therapy may also be used in other intractable pain indications such as neuropathic and inflammatory pain. Read the story in full: https://okt.to/AXkRKW #AAV #genetherapy #raredisease #nonopioid #chronicpain

Pursuing a different approach for the treatment of chronic pain associated with rare diseases, Navega Therapeutics will leverage our off-the-shelf plasmid products, custom plasmid capabilities, and GMP-grade AAV production to manufacture its next-gen gene therapy for Phase I clinical trials. With over 17m people in the US alone living with high-impact chronic pain, Navega’s non-opioid gene therapy may also be used in other intractable pain indications such as neuropathic and inflammatory pain. Read the story in full: https://okt.to/b0RXzg #AAV #genetherapy #raredisease #nonopioid #chronicpain